New pancreatic cancer pill could reshape treatment as early trial results stun researchers
A new drug, daraxonrasib, shows promise in treating pancreatic cancer, particularly for patients with RAS gene mutations. Early trial results indicate that about 30% of patients experienced a positive response, with 90% seeing their cancer shrink or stabilize. Researchers believe this drug could significantly change the landscape of pancreatic cancer treatment.
- ▪Daraxonrasib targets RAS mutations found in over 90% of pancreatic cancers.
- ▪The drug has completed an early-stage clinical trial involving 168 patients with advanced pancreatic cancer.
- ▪At the 300-milligram dose, approximately 30% of patients had a positive response to the treatment.
Fox News — Latest files mainly under news. We currently carry 3,039 of its stories.
Opening excerpt (first ~120 words) tap to expand
Health New pancreatic cancer pill could reshape treatment as early trial results stun researchers Daraxonrasib targets RAS mutations found in more than 90% of pancreatic cancers, which have had few effective therapies By Angelica Stabile Fox News Published May 18, 2026 7:00am EDT Facebook Twitter Threads Flipboard Comments Print Email Add Fox News on Google close Video FDA fast-tracks pancreatic cancer drug daraxonrasib Family and emergency medicine physician Dr. Janette Nesheiwat discusses how artificial intelligence could help detect pancreatic cancer earlier and the FDA fast-tracking the drug daraxonrasib on ‘Fox Report.’ NEWYou can now listen to Fox News articles! A new drug for pancreatic cancer is showing promise in early testing.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Fox News.
Discussion
0 commentsMore from Fox News
